close
- Africa
- EgyptWe have no local website. Please click to see local country information.
- South AfricaVisit lundbeck.co.za
- America
- ArgentinaVisit lundbeck.com.ar
- BrazilVisit lundbeck.com.br
- CanadaWe have no local website. Please click to see local country information.
- ChileVisit lundbeck.cl
- MexicoVisit lundbeck.com.mx
- United StatesVisit lundbeckresearch.us
- VenezuelaWe have no local website. Please click to see local country information.
- IndonesiaWe have no local website. Please click to see local country information.
- IsraelWe have no local website. Please click to see local country information.
- JapanVisit lundbeck.jp
- Korea, Republic ofVisit lundbeck.co.kr
- MalaysiaWe have no local website. Please click to see local country information.
- PakistanVisit lundbeck.com.pk
- PhilippinesWe have no local website. Please click to see local country information.
- Saudi ArabiaWe have no local website. Please click to see local country information.
- SingaporeWe have no local website. Please click to see local country information.
- ThailandWe have no local website. Please click to see local country information.
- TurkeyVisit lundbeck.com.tr
- United Arab EmiratesVisit gulf.lundbeck.com
- VietnamWe have no local website. Please click to see local country information.
- YemenWe have no local website. Please click to see local country information.
- Europe
- AustriaVisit lundbeck.at
- BelgiumVisit lundbeck.be
- BulgariaWe have no local website. Please click to see local country information.
- CroatiaWe have no local website. Please click to see local country information.
- Czech RepublicVisit lundbeck.cz
- DenmarkVisit lundbeck-pharma.dk
- EstoniaWe have no local website. Please click to see local country information.
- FinlandVisit lundbeck.fi
- FranceWe have no local website. Please click to see local country information.
- GermanyVisit lundbeck.de
- GreeceVisit lundbeck.gr
- HungaryWe have no local website. Please click to see local country information.
- IcelandWe have no local website. Please click to see local country information.
- IrelandVisit lundbeck.ie
- ItalyVisit lundbeck.it
- LatviaVisit lundbeck.lv
- LithuaniaWe have no local website. Please click to see local country information.
- NederlandsVisit lundbeck.nl
- NorwayVisit lundbeck.no
- PolandVisit lundbeck.pl
- PortugalWe have no local website. Please click to see local country information.
- RomaniaWe have no local website. Please click to see local country information.
- Russian FederationVisit lundbeck.ru
- SlovakiaWe have no local website. Please click to see local country information.
- SloveniaWe have no local website. Please click to see local country information.
- SpainVisit lundbeck.es
- SwedenVisit lundbeck.se.
- SwitzerlandVisit lundbeck.ch.
- UkraineWe have no local website. Please click to see local country information.
- United KingdomVisit lundbeck.uk
- Oceania
- AustraliaVisit lundbeck.com.au
- Other Lundbeck sites
- CNSforumVisit the CNF forum website
- Cipralex.comVisit the Cipralex website
- Ebixa.comVisit the Ebixa website
- Azilect.comVisit the Azilect website
- Serdolect.comVisit the Serdolect website
- DepNet.comVisit the DepNet website
- Dementia.comVisit the Dementia website
- BrainExplorer.orgVisit the BrainExplorer website
- Psychotropics onlineVisit the Psychotropics website
For local information please click here
Contact us
Lundbeck in-licenses Circadin®, a drug approved for the treatment of primary insomnia from Neurim Pharmaceuticals
| H. Lundbeck A/S and Neurim Pharmaceuticals Ltd. today announced that Lundbeck has in-licensed the exclusive rights for Circadin® for the treatment of primary insomnia for the majority of markets in Europe including the five major markets. Furthermore, Lundbeck holds the exclusive option to evaluate commercialization in markets outside of Europe. Circadin®, a novel sleep aid, was approved by the European Commission 29 June 2007 indicated as monotherapy for the short-term treatment of primary insomnia characterized by poor quality of sleep in patients who are aged 55 or over. The approval was based on clinical studies showing positive effects on both sleep induction, sleep quality, and most importantly, day-time-functioning as well as quality of life. The trials also show that there are no signs of development of dependency. Lundbeck expects to launch Circadin® in the first markets during 2008.
Under the terms of the agreement Neurim receives an upfront payment and a share of revenue. Neurim is responsible for manufacturing.
"We are delighted to have licensed Circadin® to a company with a strong track record within the research, development, marketing and sales of medicines for the treatment of central nervous system disorders", says Prof. Nava Zisapel, CSO of Neurim Pharmaceuticals. "We are confident that with Lundbeck as our partner we will be able to realize the full potential of Circadin® to the benefit of patients."
"Circadin® has shown to be a unique treatment of poor sleep with a new mechanism different from all other approved medicines. Circadin® mimics the physiological profile of the body's own melatonin secretion and will be a very valuable alternative to traditional sedative hypnotics, which share a number of drawbacks, such as dependency and residual drowsiness" says Executive Vice President Stig Løkke Pedersen, head of Commercial Operations.
About Circadin®
Circadin® is the first and only IP-protected prolonged-release, melatonin containing ethical drug approved in the EU. Melatonin is a naturally occurring hormone produced by the pineal gland; it has a pivotal role in the regulation of circadian rhythms and sleep. Endogenous melatonin levels decrease with age and may contribute to the common complaint of poor sleep quality seen amongst those in middle age and in the elderly. Administration of Circadin®, which essentially mimics the normal nocturnal melatonin profile, improves sleep quality and morning alertness and facilitates sleep onset in patients aged 55 or over.
The content of this release will have no influence on the Lundbeck Group's financial result for 2007.
Neurim contact
Lundbeck contacts
________________________
Stock Exchange Release No 295 - 24 September 2007
About Neurim
Neurim Pharmaceuticals Ltd. (1991), headquartered in Israel with a business development unit in Switzerland, is a drug discovery and development company founded in 1991. Neurim is focused on age-related disorders, primarily in the central nervous system (CNS). The main goal is to improve the quality of life in the older patient population. Circadin® is the company's first product reaching marketing approval. Other products are at various stages of preclinical and clinical development. For further information, please visit www.neurim.com
About Lundbeck
H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2006, the company's revenue was DKK 9.2 billion (approximately EUR 1.2 billion or USD 1.6 billion). The number of employees is approximately 5,300 globally. For further information, please visit www.lundbeck.com |
Read also
H. Lundbeck A/S
Ottiliavej 9
DK-2500 Copenhagen Valby
Ottiliavej 9
DK-2500 Copenhagen Valby
Phone +45 36 30 13 11
Fax +45 36 44 93 04
Fax +45 36 44 93 04
The specialist in psychiatry and pioneer in neurology
Disclaimer
Disclaimer